Pfizer Inc.
DLL3 TARGETING CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS

Last updated:

Abstract:

Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.

Status:
Application
Type:

Utility

Filling date:

27 Feb 2020

Issue date:

15 Apr 2021